Jonathan Zalevsky sold $58k of NKTR
Chief R&D Officer at NEKTAR THERAPEUTICS. 1,721 shares at an average of $33.52, traded Sep 4, 2025, filed Sep 8, 2025.
Score components
- +15RoleOfficer
- +7Trade size$58k at market
- 0Share of holdings soldSold 9.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +27.6%, 3m +29.2%, 6m +56.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113692, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -793 | $32.43 | $26k | 18,390 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -432 | $33.60 | $15k | 17,958 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -189 | $34.41 | $6,503 | 17,769 | Sep 8, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -307 | $35.69 | $11k | 17,462 | Sep 8, 2025 |
Related signals
Other insiders at NEKTAR THERAPEUTICS and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $1.2M 20,000 shares | -27% | |
| 28Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $336k 5,538 shares | -26% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $29k 444 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 199 shares | -1% | |
| 38Weak | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $31k 423 shares | -1% | |
| 23Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $13k 180 shares | -1% | |
| 11Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $138k 3,867 shares | -15% | |
| 50Moderate | NEKTAR THERAPEUTICS | Howard W Robin President & CEO | $120k 2,207 shares | -4% | |
| 36Weak | NEKTAR THERAPEUTICS | Mark Andrew Wilson Chief Legal Officer | $34k 630 shares | -3% | |
| 38Weak | NEKTAR THERAPEUTICS | Jonathan Zalevsky Chief R&D Officer | $63k 1,157 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.